The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Estracyt     (17-hydroxy-13-methyl- 6,7,8,9,11,12,14,15...

Synonyms: CHEMBL1575, Leo-275, LEO 275, AC1L2BFB, NSC89201, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of estramustine


Psychiatry related information on estramustine


High impact information on estramustine


Chemical compound and disease context of estramustine


Biological context of estramustine


Anatomical context of estramustine


Associations of estramustine with other chemical compounds


Gene context of estramustine


Analytical, diagnostic and therapeutic context of estramustine


  1. Disappearance of osteoblastic metastases in prostatic carcinoma following estramustine therapy. Catane, R., Kaufman, J., Mittelman, A., Murphy, G.P. JAMA (1977) [Pubmed]
  2. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Panda, D., Miller, H.P., Islam, K., Wilson, L. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  3. Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. Bergenheim, A.T., Björk, P., Bergh, J., von Schoultz, E., Svedberg, H., Henriksson, R. Cancer Res. (1994) [Pubmed]
  4. Estramustine sensitizes human glioblastoma cells to irradiation. Yoshida, D., Piepmeier, J., Weinstein, M. Cancer Res. (1994) [Pubmed]
  5. "Skittish" Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system. Mack, J.T., Beljanski, V., Soulika, A.M., Townsend, D.M., Brown, C.B., Davis, W., Tew, K.D. Mol. Cell. Biol. (2007) [Pubmed]
  6. A time study on the uptake of estramustine into prostatic tumour 1013L cells in vitro. Kruse, E., Hartley-Asp, B. Biochem. Pharmacol. (1989) [Pubmed]
  7. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. Speicher, L.A., Barone, L.R., Chapman, A.E., Hudes, G.R., Laing, N., Smith, C.D., Tew, K.D. J. Natl. Cancer Inst. (1994) [Pubmed]
  8. Modulation of the function of P-glycoprotein by estramustine. Yang, C.P., Shen, H.J., Horwitz, S.B. J. Natl. Cancer Inst. (1994) [Pubmed]
  9. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Tu, S.M., Millikan, R.E., Mengistu, B., Delpassand, E.S., Amato, R.J., Pagliaro, L.C., Daliani, D., Papandreou, C.N., Smith, T.L., Kim, J., Podoloff, D.A., Logothetis, C.J. Lancet (2001) [Pubmed]
  10. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. Stearns, M.E., Wang, M., Tew, K.D., Binder, L.I. J. Cell Biol. (1988) [Pubmed]
  11. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Petrylak, D.P., Macarthur, R.B., O'Connor, J., Shelton, G., Judge, T., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D., Fine, R., Zuech, N., Sawczuk, I., Benson, M., Olsson, C.A. J. Clin. Oncol. (1999) [Pubmed]
  12. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Kelly, W.K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D., Ciolino, A., Regan, K., Schwartz, M., Kantoff, P., George, D., Oh, W., Smith, M., Kaufman, D., Small, E.J., Schwartz, L., Larson, S., Tong, W., Scher, H. J. Clin. Oncol. (2001) [Pubmed]
  13. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Low, J.A., Wedam, S.B., Lee, J.J., Berman, A.W., Brufsky, A., Yang, S.X., Poruchynsky, M.S., Steinberg, S.M., Mannan, N., Fojo, T., Swain, S.M. J. Clin. Oncol. (2005) [Pubmed]
  14. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. Galsky, M.D., Small, E.J., Oh, W.K., Chen, I., Smith, D.C., Colevas, A.D., Martone, L., Curley, T., Delacruz, A., Scher, H.I., Kelly, W.K. J. Clin. Oncol. (2005) [Pubmed]
  15. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. Millikan, R., Thall, P.F., Lee, S.J., Jones, D., Cannon, M.W., Kuebler, J.P., Wade, J., Logothetis, C.J. J. Clin. Oncol. (2003) [Pubmed]
  16. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Yamaguchi, H., Paranawithana, S.R., Lee, M.W., Huang, Z., Bhalla, K.N., Wang, H.G. Cancer Res. (2002) [Pubmed]
  17. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol. Forsgren, B., Gustafsson, J.A., Pousette, A., Högberg, B. Cancer Res. (1979) [Pubmed]
  18. Blocking of collagenase secretion by estramustine during in vitro tumor cell invasion. Wang, M., Stearns, M.E. Cancer Res. (1988) [Pubmed]
  19. Expression of an estramustine-binding associated protein in human lung cancer cell lines. Bergh, J., Björk, P., Westlin, J.E., Nilsson, S. Cancer Res. (1988) [Pubmed]
  20. Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve. Kanje, M., Deinum, J., Wallin, M., Ekström, P., Edström, A., Hartley-Asp, B. Cancer Res. (1985) [Pubmed]
  21. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma. Neubauer, B.L., Best, K.L., Goode, R.L., Heiman, M.L., Hoover, D.M., Robertson, D.W., Sarosdy, M.F., Shaar, C.J., Tanzer, L.R., Merriman, R.L. Cancer Res. (1992) [Pubmed]
  22. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. Pettaway, C.A., Pisters, L.L., Troncoso, P., Slaton, J., Finn, L., Kamoi, K., Logothetis, C.J. J. Clin. Oncol. (2000) [Pubmed]
  23. Systemic treatment for prostate cancer. Lyss, A.P. Am. J. Med. (1987) [Pubmed]
  24. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Oh, W.K., Hagmann, E., Manola, J., George, D.J., Gilligan, T.D., Jacobson, J.O., Smith, M.R., Kaufman, D.S., Kantoff, P.W. Clin. Cancer Res. (2005) [Pubmed]
  25. Effects of diethylstilbestrol and estramustine phosphate (estracyt) on natural killer cell activity and tumor susceptibility in male mice. Kalland, T., Haukaas, S.A. Prostate (1984) [Pubmed]
  26. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Laing, N.M., Belinsky, M.G., Kruh, G.D., Bell, D.W., Boyd, J.T., Barone, L., Testa, J.R., Tew, K.D. Cancer Res. (1998) [Pubmed]
  27. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Mani, S., Huang, H., Sundarababu, S., Liu, W., Kalpana, G., Smith, A.B., Horwitz, S.B. Clin. Cancer Res. (2005) [Pubmed]
  28. Regulation of Cyp1a1 induction by dioxin as a function of cell cycle phase. Santini, R.P., Myrand, S., Elferink, C., Reiners, J.J. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  29. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Wang, L.G., Liu, X.M., Kreis, W., Budman, D.R. Biochem. Pharmacol. (1998) [Pubmed]
  30. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Griffin, D., Wittmann, S., Guo, F., Nimmanapalli, R., Bali, P., Wang, H.G., Bhalla, K. Gynecol. Oncol. (2003) [Pubmed]
  31. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17 beta. Forsgren, B., Björk, P., Carlström, K., Gustafsson, J.A., Pousette, A., Högberg, B. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
WikiGenes - Universities